These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 4040664)

  • 1. Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.
    Ohara T; Ogata H; Fujiyama J; Murata Y; Abe J; Kakuta K; Hayamizu S; Kameyama S; Yoshida Y
    Tohoku J Exp Med; 1985 Jun; 146(2):237-49. PubMed ID: 4040664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of prostaglandin E1 in neonates with critical congenital cardiac defects.
    Lewis AB; Takahashi M; Lurie PR
    J Pediatr; 1978 Sep; 93(3):481-5. PubMed ID: 690772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E1 in infants with congenital heart disease: Indian experience.
    Saxena A; Sharma M; Kothari SS; Juneja R; Reddy SC; Sharma R; Bhan A; Venugopal P
    Indian Pediatr; 1998 Nov; 35(11):1063-9. PubMed ID: 10216540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic dilatation of the ductus arteriosus with prostaglandin E1 in infants with congenital heart disease.
    Graham TP; Atwood GF; Boucek RJ
    South Med J; 1978 Oct; 71(10):1238-41, 1246. PubMed ID: 81528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA; Clyman RI
    Pharmacotherapy; 1982; 2(3):148-55. PubMed ID: 6763200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Congenital heart disease and respiratory distress syndrome. Reversal of indomethacin closure of patent ductus arteriosus by prostaglandin therapy in a preterm infant.
    Strauss A; Modanlou HD; Gyepes M; Wittner R
    Am J Dis Child; 1982 Oct; 136(10):934-6. PubMed ID: 6889810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of prostaglandin E1 in cardiac malformations in the newborn infant].
    Sassolas F; Bozio A; Andre M; Jocteur-Monrozier D; Champsaur G; Normand J
    Pediatrie; 1984 Jun; 39(4):245-52. PubMed ID: 6504667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1: first stage palliation in neonates with congenital cardiac defects.
    Reddy SC; Saxena A
    Indian J Pediatr; 1998; 65(2):211-6. PubMed ID: 10771966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 in infants with pulmonary atresia.
    Weir EK; Matisonn RE; Losman E; Chesler E
    S Afr Med J; 1978 Oct; 54(17):700-2. PubMed ID: 741285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of prostaglandin E1 on the hemodynamics in newborn infants with pulmonary atresia (author's transl)].
    Mocellin R; Sauer U; Schumacher G; Kellner M; Schöber JG
    Z Kardiol; 1978 Aug; 67(8):572-7. PubMed ID: 695809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prostaglandin E1 therapy in congenital heart defects.
    Teixeira OH; Carpenter B; MacMurray SB; Vlad P
    J Am Coll Cardiol; 1984 Mar; 3(3):838-43. PubMed ID: 6537955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].
    Fujii S; Nagai I; Yonei A; Sari A; Baba K
    Masui; 1984 May; 33(5):545-9. PubMed ID: 6540818
    [No Abstract]   [Full Text] [Related]  

  • 13. Alprostadil (Prostin VR Pediatric Sterile Solution, The Upjohn Company).
    Roehl SL; Townsend RJ
    Drug Intell Clin Pharm; 1982 Nov; 16(11):823-32. PubMed ID: 6756848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dilatation of the ductus arteriosus by prostaglandin E1 in aortic arch abnormalities.
    Heymann MA; Berman W; Rudolph AM; Whitman V
    Circulation; 1979 Jan; 59(1):169-73. PubMed ID: 758109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandins and the management of congenital heart disease.
    Taylor WJ; Alpert BS
    Am Fam Physician; 1982 Dec; 26(6):127-32. PubMed ID: 6890758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS; Nihill MR; Titus JL
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prostaglandins E1 in the treatment of neonatal cardiopathies related to ductus arteriosus. 19 cases].
    Maesen Y; Bosi G; Stijns M; Vliers A
    Arch Mal Coeur Vaiss; 1981 May; 74(5):579-85. PubMed ID: 6794479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E1 treatment in patent ductus arteriosus dependent congenital heart defects.
    Tálosi G; Katona M; Rácz K; Kertész E; Onozó B; Túri S
    J Perinat Med; 2004; 32(4):368-74. PubMed ID: 15346826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nursing care of the neonate receiving prostaglandin E1 therapy.
    Rikard DH
    Neonatal Netw; 1993 Jun; 12(4):17-22. PubMed ID: 8510622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of the ductus arteriosus.
    Rudolph AM; Heymann MA
    Hosp Pract; 1977 Feb; 12(2):57-65. PubMed ID: 557025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.